R-HU-EPO FOR ANEMIA OF PREMATURITY

早产儿贫血是红细胞输注的主要原因 在新生儿重症监护室大多数极低出生体重儿 接受多次输血EPO产量不足， 贫血是导致早产儿闭经的因素之一。试验 的r-Hu-EPO给予稳定的，年龄较大的婴儿已经表明它是一种安全的， 有效治疗早产儿贫血。本研究旨在 确定是否非常早期治疗极早产儿 在减少输血方面将比目前的 在出生后2-3周开始治疗的做法。 状态：该多中心研究可能未在UCSF实施。 迄今为止开展的活动包括r-Hu-EPO相关介绍， 出版物。

Anemia of prematurity is the major cause for red blood cell transfusions in the neonatal intensive care unit. Most very low birthweight infants receive multiple transfusions. Inadequate production of EPO in response to anemia is one of the factors contributing to amenia of prematurity. Trials of r-Hu-EPO given to stable, older infants have shown it to be a safe and effective treatment for anemia of prematurity. This study is undertaken to determine whether very early treatment of extremely premature infants with will have a greater effect in reducing transfusions than the current practice of beginning treatment at 2-3 weeks after birth. Status: This multi-centered study may not be implemented at UCSF. Activities undertaken to date include r-Hu-EPO related presentations and publications.